Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
| ▸ | GRK5 | P34947 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.48 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 14/20 | 0.40 |
| ▸ | JAK1 | P23458 | 14/20 | 0.40 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464715 | 0.83 | NUDT1 (0.51) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL4458185 | 0.74 | JAK1 (0.42) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL24678884 | 0.73 | PRKCI (0.47) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL13711502 | 0.72 | BRAF (0.43) | RETBTKALDH1A1 | |
| SCHEMBL13711476 | 0.72 | MAP3K20 (0.41) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL13708181 | 0.72 | MAPT (0.50) | — | |
| SCHEMBL1134918 | 0.69 | FGFR1 (0.55) | JAK3RETFGFR1BTKMAP4K2 | |
| SCHEMBL2316035 | 0.69 | JAK2 (0.44) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL13579552 | 0.69 | JAK1 (0.48) | JAK3RETFGFR1LTKGRK5 | |
| SCHEMBL17122716 | 0.69 | JAK3 (0.58) | JAK3RETFGFR1LTKGRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | claimed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | claimed |
| EP-1919924-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-05-14 | — | — | EP | claimed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | claimed |
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | disclosed |
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | disclosed |
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | disclosed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| EP-1919924-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | AURKC, PTK2B, FRK | JAK3 204/4885RET 21/4885FGFR1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.